Tuesday, 10.24.2017, Baltimore, MD, Insilico Medicine, a leader in the field of artificial intelligence, is pleased to announce its founder and CEO, Dr. Alex Zhavoronkov, will present at The World Congress on Targeting Metabesity in London, UK on Tuesday, October 31 in Session VIII: Are New Business Models Needed?
Dr. Zhavoronkov's presentation will focus on recent advances in artificial intelligence specifically in deep learning allow for novel ways to identify the disease targets, generate novel molecular structures for these targets, track the effects of the various interventions and improve behavior.
Metabesity refers to the major public health challenges--cardiovascular disease, cancer, dementia, diabetes and the aging process itself--all of which share metabolic roots. These metabolically connected disorders can be targeted to prevent--not just manage them. Metabesity2017 aims at these stretch goals by engaging world-renowned scientific experts, executives, policy makers, and other stakeholders across the fields of metabolic-rooted disorders. The distinctive objective of Metabesity2017 is to devise cross-cutting strategies to leverage impact of this science and technology.
Dr. Zhavoronkov, PhD, founder and CEO of Insilico Medicine, Inc said, "Targeting metabesity is the low-hanging fruit for extending human longevity and improving the quality of life. Recent advances in artificial intelligence specifically in deep learning allow for novel ways to identify the disease targets, generate novel molecular structures for these targets, track the effects of the various interventions and improve behavior. We are very happy to present our work at this unique and most important conference, Metabesity2017, which will catalyze interdisciplinary progress."
Dr. Alexander Fleming, Founder and Chairman of Kinexum, commented: "We are delighted to have Alex participate in this inaugural congress, which annually will help to accelerate collaboration, creativity, and productivity in the fields of chronic disease prevention and healthy lifespan extension. He has not only contributed immensely to scientific and technical progress, but he is the personal embodiment of what the Metabesity movement aims to be--connecting and invigorating disparate experts, institutions, and resources to pursue daunting goals.
For further information, images or interviews, please contact:
Contact: Qingsong Zhu, PhD
About Insilico Medicine, Inc
Insilico Medicine, Inc. is an artificial intelligence company located at the Emerging Technology Centers at the Johns Hopkins University Eastern campus in Baltimore, with R&D resources in Belgium, Russia, and the UK sourced through hackathons and competitions.
The company utilizes advances in genomics, big-data analysis, and deep learning for in silico drug discovery and drug repurposing for aging and age-related diseases. The company is pursuing internal drug discovery programs in cancer, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging.
Through its Pharma.AI division, Insilico provides advanced machine learning services to biotechnology, pharmaceutical, and skin care companies, foundations and national governments globally. In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. http://www.insilico.com
Kinexum catalyze academic and commercial efforts to develop health products aimed at treatment and prevention of major chronic diseases as well as orphan conditions. Kinexum experts provide guidance across the spectrum of pharmaceuticals, biologics, cell therapies, nutritionals, medical devices, and digital health. Kinexum contributes, pro bono, substantially to advancing regulatory science and policy, generating guidelines and scientific publications, leading professional organizations, and bringing a diversity of experts and decision makers together. http://www.kinexum.com